Angiotensin is a peptide hormone family (primarily angiotensin II, Ang II) that serves as the primary effector molecule of the RAA-system, functioning as a potent vasoconstrictor, Aldosterone secretagogue, and pro-inflammatory signaling molecule. Activated during acute stress response and volume depletion (>10-15% blood volume loss), angiotensin II binds AT1 receptors to orchestrate cardiovascular, metabolic, and immune responses. The counter-regulatory axis (ACE2/Ang 1-7/MAS receptor) provides anti-inflammatory balance.
Think of the angiotensin system as a municipal emergency response to a water shortage (low blood volume or pressure). When pressure drops in the water mains (blood vessels), sensors in the kidney pump station (juxtaglomerular cells) release renin β the emergency foreman. Renin cuts a long, dormant pipe section (angiotensinogen) into a workable piece (angiotensin I), but it's still not fully functional. At the neighborhood level (lungs, endothelium), a specialized crew (ACE enzyme) makes the final cut, creating angiotensin II β the city's emergency dispatcher.
This dispatcher (Ang II) does three critical things simultaneously: first, it radios all street-level valves (blood vessels) to constrict immediately, raising pressure throughout the system. Second, it calls the city water manager (adrenal glands) to activate aldosterone β the water retention hormone that tells the kidney filtration plant to stop releasing water and salt. Third β and this is where cPNI gets interesting β the dispatcher also activates the city's defense forces (immune system), putting inflammatory cells on high alert through the same emergency radio frequency (NF-ΞΊB activation). It's a survival response: conserve fluid, maintain pressure, prepare for infection.
But here's the problem: if the emergency dispatcher keeps broadcasting 24/7 (chronic RAA-system activation), the constantly constricted pipes develop stress fractures (endothelial dysfunction), the water retention floods the system (hypertension, edema), and the constantly-activated defense forces start attacking healthy neighborhoods (chronic inflammation, atherosclerosis). The city's backup system (ACE2) tries to cut the emergency signal into a calming message (Ang 1-7), but in chronic stress states, the emergency channel drowns out the all-clear.
The angiotensin cascade involves sequential enzymatic cleavages producing peptides with opposing biological actions:
graph TD
A["Angiotensinogen<br/>liver production"] -->|"Renin<br/>JG cells"| B["Angiotensin I<br/>10 amino acids"]
B -->|"ACE<br/>lung/endothelium"| C["Angiotensin II<br/>8 amino acids"]
B -->|ACE2| D[Ang 1-9]
C -->|AT1 Receptor| E[Vasoconstriction]
C -->|AT1 Receptor| F[Aldosterone Secretion]
C -->|AT1 Receptor| G[Sympathetic Activation]
C -->|AT1 Receptor| H["NF-ΞΊB Activation"]
C -->|ACE2| I[Ang 1-7]
I -->|MAS Receptor| J[Vasodilation]
I -->|MAS Receptor| K[Anti-inflammatory]
H --> L[NADPH Oxidase]
L --> M[ROS Production]
H --> N[Pro-inflammatory Cytokines]
N --> O["IL-6, TNF-Ξ±, IL-1Ξ²"]
Step 1: Renin Release
- Juxtaglomerular (JG) cells in kidney afferent arteriole detect:
- β renal perfusion pressure (<90 mmHg systolic)
- β NaCl delivery to macula densa
- Ξ²1-adrenergic stimulation via sympathetic nervous system
- Renin cleaves hepatic angiotensinogen β angiotensin I (decapeptide)
Step 2: ACE Conversion
- ACE (angiotensin-converting enzyme) on pulmonary and systemic endothelium cleaves angiotensin I β angiotensin II (octapeptide, Ang II)
- ACE also degrades Bradykinin (vasodilator), dual action increasing vasoconstriction
- Peak Ang II production occurs in lungs (first-pass metabolism) and peripheral vasculature
Step 3: AT1 Receptor Activation
Ang II binding to AT1 receptors (Gq-coupled GPCR) triggers:
- Vascular smooth muscle: phospholipase C β IP3/DAG β CaΒ²βΊ release β myosin light chain kinase β vasoconstriction (within 30-60 seconds)
- Adrenal zona glomerulosa: β Aldosterone synthesis β renal NaβΊ/HβO retention, KβΊ excretion
- Sympathetic ganglia: enhanced Noradrenaline release, β Adrenaline from adrenal medulla
- Hypothalamus: β AVP (vasopressin) release, thirst stimulation at subfornical organ (Circumventricular organs)
- Endothelial cells: NADPH oxidase activation β Reactive Oxygen Species (superoxide, Oββ») β Oxidative Stress
- Immune activation: NF-ΞΊB translocation β transcription of IL-6, TNF-Ξ±, IL-1Ξ², adhesion molecules (VCAM-1, ICAM-1)
- Cardiac/vascular remodeling: β collagen synthesis, fibroblast proliferation, hypertrophy signaling via ERK1/2, AKT pathway
Step 4: Counter-Regulatory Axis
- ACE2 converts Ang II β Ang 1-7 (heptapeptide)
- Ang 1-7 binds MAS receptor (Gq-coupled) β opposing effects:
- Vasodilation via NO/Bradykinin pathways
- Anti-inflammatory signaling (β NF-ΞΊB, β IL-10)
- Anti-fibrotic effects
- ACE2 also converts angiotensin I β Ang 1-9 β Ang 1-7
- ACE2 is expressed in lung, kidney, heart, gut β critical for SARS-CoV-2 viral entry (COVID-19 connection)
Inflammatory Cascade Detail:
AT1 receptor β Gq protein β phospholipase C β PKC activation β NF-ΞΊB (p50/p65) nuclear translocation β binding to promoter regions of:
- IL-6 (pro-inflammatory, induces acute phase response)
- TNF-Ξ± (endothelial activation, fever, cachexia)
- IL-1Ξ² (pyrogenic, cartilage degradation)
- MCP-1 (monocyte chemotaxis)
- COX-2 (prostaglandin synthesis)
- iNOS (nitric oxide, peroxynitrite formation with superoxide)
NADPH oxidase (NOX) activation:
AT1 receptor β p47phox phosphorylation β assembly of NOX complex β electron transfer from NADPH to Oβ β superoxide (Oββ») β hydrogen peroxide (HβOβ) β hydroxyl radical (Β·OH)
ROS effects:
- LDL oxidation β foam cell formation (atherosclerosis)
- Protein nitrosylation β enzyme dysfunction
- DNA damage β cellular senescence
- Endothelial Nitric Oxide quenching β β vasodilation, β platelet aggregation
The angiotensin system sits at the intersection of Stress Axis Desynchronization, chronic low-grade inflammation, and metabolic syndrome β a triple threat in cPNI practice.
Stress Axis Integration: Angiotensin II is co-activated with Cortisol and Noradrenaline during the acute stress response. While cortisol peaks at 20-30 minutes post-stressor, Ang II rises within 5-10 minutes of sympathetic activation, representing the fastest hormonal vasoconstrictor. In chronic stress, perpetual RAA-system activation creates:
Selfish Systems Conflict: The cardiovascular system's "selfish" demand for blood pressure maintenance (Ang II vasoconstriction + aldosterone volume expansion) conflicts with:
- Selfish Brain: chronic hypertension β microvascular damage β cognitive decline, vascular dementia
- selfish immune system: Ang II immune activation diverts metabolic resources, creating Metabolic Depression
- Muscle/metabolism: chronic vasoconstriction β β tissue perfusion β β Insulin sensitivity, β nutrient delivery
Evolutionary Mismatch: The RAA-system evolved for acute hemorrhage or dehydration (survival-critical volume loss). Modern chronic stressors (psychological stress, sleep deprivation, sedentarism, high-sodium diet) activate this system daily without actual volume depletion. The Evolutionary mismatch manifests as:
Clinical Biomarkers:
- Plasma renin activity (PRA): 0.2-2.8 ng/mL/hr (high in volume depletion, low in primary aldosteronism)
- Plasma aldosterone concentration (PAC): 4-31 ng/dL (upright); aldosterone:renin ratio >20 suggests primary hyperaldosteronism
- Serum Ang II: rarely measured clinically (unstable, expensive); typically 10-30 pg/mL
- ACE2 shedding (soluble ACE2): β in COVID-19, heart failure, diabetes
- Urinary aldosterone: 2-80 Β΅g/24hr (reflects integrated RAA-system activity)
Patient Populations:
- Chronic stress/PTSD: persistent sympathetic overdrive β chronic RAA-system activation β early-onset hypertension, especially in adverse childhood experiences (ACEs) cohorts
- Metabolic syndrome: visceral adiposity β adipocyte renin/angiotensinogen β local tissue RAA-system β adipose inflammation, Insulin resistance
- Chronic Kidney Disease: β GFR β β renal perfusion β renin secretion β vicious cycle of Ang II-mediated glomerular damage
- Heart failure: β cardiac output β renin release β Ang II β afterload β β further cardiac strain; aldosterone β myocardial fibrosis
- Inflammatory bowel disease, Rheumatoid arthritis: tissue RAA-system expression β local Ang II β inflammatory cytokine amplification
Intervention Implications:
- ACE inhibitors (e.g., lisinopril, enalapril): block Ang I β Ang II conversion; clinical benefits beyond BP lowering include β IL-6, β CRP, β cardiovascular events (HOPE trial: 22% reduction in MI/stroke/death)
- ARBs (angiotensin receptor blockers): block AT1 receptors; may spare AT2 receptor (vasodilatory, anti-proliferative) and allow ACE2 pathway function
- Aldosterone antagonists (spironolactone): block Mineralocorticoid Receptor β β NaβΊ retention, β myocardial fibrosis, β inflammation (RALES trial: 30% mortality reduction in heart failure)
- Lifestyle modulators:
- Sodium restriction (<2.3 g/day): β volume expansion β β Ang II-independent hypertension
- Exercise: β ACE2 expression, β Ang 1-7 (anti-inflammatory shift)
- Omega-3 fatty acids (EPA/DHA): β AT1 receptor expression, β Ang II-induced NF-ΞΊB
- Polyphenols (resveratrol, EGCG): β ACE2 activity, β AT1 signaling
- Stress reduction (Meditation, breathwork): β sympathetic tone β β renin release
- Phytotherapy:
- Hibiscus (Hibiscus sabdariffa): natural ACE inhibitor (comparable to low-dose captopril in mild hypertension)
- Hawthorn (Crataegus): ACE inhibition + vasodilation via NO
- Aged garlic extract: β Ang II-induced vasoconstriction
Exam-Relevant Integration: Angiotensin II represents a stress-inflammation-metabolism nexus. In exam scenarios involving hypertension + Insulin resistance + elevated CRP, think RAA-system hyperactivation. If the patient also has chronic stress, obesity, or sleep disorders, you're seeing Stress Axis Desynchronization with metabolic-immune crosstalk. The treatment approach must address the stress input (psychology module), sodium/nutrient status (metabolism module), and inflammatory signaling (immune module) β pure blood pressure management misses 2/3 of the pathophysiology.
- Activation threshold: 10-15% circulating volume loss or systolic BP <90 mmHg triggers renin release
- Timeline: Ang II peaks 5-10 min post-stressor (faster than cortisol's 20-30 min peak)
- Vasoconstriction potency: Ang II is 40Γ more potent than Noradrenaline per molecule at raising blood pressure
- Half-life: Ang II circulating half-life is 30-60 seconds (rapid degradation by peptidases); tissue effects persist hours via autocrine/paracrine signaling
- Tissue RAA-system: adipose, heart, kidney, brain, vasculature all produce local angiotensin independently of circulating renin (accounts for 70-90% of tissue Ang II)
- ACE2/ACE ratio: β ratio associated with disease severity in COVID-19, heart failure, diabetes; ACE2 is protective counter-regulatory enzyme
- NF-ΞΊB threshold: Ang II concentrations >10β»βΉ M activate NF-ΞΊB in endothelial cells β IL-6, TNF-Ξ± transcription
- Aldosterone effect: peak sodium retention occurs 24-48 hours after aldosterone surge (genomic mechanism via Mineralocorticoid Receptor)
- ROS production: AT1 receptor activation β 2-5 fold increase in vascular superoxide within 15 minutes (NADPH oxidase-dependent)
- Clinical BP response: ACE inhibitors/ARBs reduce systolic BP by 10-15 mmHg on average; greater effect in high-renin hypertension (young, white, stressed patients) vs low-renin (elderly, black, salt-sensitive)
- Anti-inflammatory effect: ARBs reduce CRP by 20-40% independent of BP lowering (LIFE study)
- Cognitive impact: chronic Ang II β cerebral microvascular damage β white matter hyperintensities β β processing speed, executive function (Framingham data)
- Diabetogenic effect: Ang II β β pancreatic blood flow, β islet oxidative stress, β Insulin secretion; ACE inhibitors reduce new-onset diabetes by 14-34% (clinical trials meta-analysis)
- Evolutionary medicine context: high-renin phenotype (rapid Ang II response) selected in low-salt environments; maladaptive in modern high-sodium context
- Cortisol β co-activated during acute stress response; both peak within 30 min, create synergistic vasoconstriction and immune modulation
- Noradrenaline β co-activated stress hormone; stimulates renin release via Ξ²1-adrenergic receptors; Ang II enhances noradrenaline release at sympathetic nerve terminals
- Aldosterone β primary downstream effector of Ang II; mediates NaβΊ/HβO retention, drives Mineralocorticoid Receptor activation in kidney, heart, brain
- ACE β converting enzyme that produces Ang II from angiotensin I; also degrades vasodilatory Bradykinin, creating dual hypertensive effect
- ACE2 β counter-regulatory enzyme converting Ang II β Ang 1-7; protective against inflammation, fibrosis; SARS-CoV-2 receptor
- Ang 1-7 β anti-inflammatory, vasodilatory peptide product of ACE2; binds MAS receptor; opposes AT1 signaling
- NF-ΞΊB β transcription factor activated by AT1 receptor signaling; upregulates IL-6, TNF-Ξ±, IL-1Ξ², COX-2
- Reactive Oxygen Species β produced via Ang II-stimulated NADPH oxidase; drives Oxidative Stress, endothelial dysfunction, LDL oxidation
- IL-6 β pro-inflammatory cytokine transcribed via Ang II β NF-ΞΊB; drives acute phase response, Insulin resistance
- TNF-Ξ± β pro-inflammatory cytokine induced by Ang II; promotes endothelial activation, cachexia, insulin resistance
- Insulin resistance β Ang II disrupts Insulin receptor substrate-1 (IRS-1) signaling via inflammatory pathways (JNK, IKK); impairs GLUT4 translocation
- endothelial dysfunction β Ang II-induced ROS quenches Nitric Oxide, reduces flow-mediated dilation; early marker of atherosclerosis
- atherosclerosis β Ang II promotes LDL oxidation, foam cell formation, vascular smooth muscle proliferation, plaque instability
- Chronic Kidney Disease β Ang II causes glomerular hyperfiltration, podocyte injury, mesangial expansion, tubulointerstitial fibrosis
- sympathetic nervous system β stimulates renin release; Ang II enhances sympathetic outflow via central effects at Circumventricular organs
- AVP β vasopressin released by Ang II action at subfornical organ; synergistic with Ang II for vasoconstriction and water retention
- Stress Axis Desynchronization β chronic Ang II activation represents persistence of emergency cardiovascular response despite absence of volume loss
- chronic low-grade inflammation β tissue RAA-system activation creates sterile inflammation via AT1 β NF-ΞΊB in absence of infection
- metabolic syndrome β Ang II links visceral adiposity β inflammation β Insulin resistance; adipocyte-derived angiotensinogen contributes to systemic activation
- Type 2 Diabetes β Ang II impairs pancreatic beta cell function, reduces insulin secretion, promotes insulin resistance; ACE inhibitors reduce diabetes incidence
- NAFLD β hepatic RAA-system activation promotes steatosis, inflammation (NASH), fibrosis via oxidative stress and inflammatory signaling
- Omega-3 fatty acids β EPA/DHA reduce AT1 receptor expression, inhibit Ang II-induced NF-ΞΊB, shift toward ACE2/Ang 1-7 axis